The endotoxin-induced neuroinflammation model of Parkinson's disease

Parkinson's Disease

Volumn , Issue , 2011, Pages

  Genc, Kursad ^a   Tufekci, Kemal Ugur ^a   Genc, Sermin ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; ENDOTOXIN; IBUPROFEN; LIPOPOLYSACCHARIDE; LIPOXYGENASE; MELOXICAM; MINOCYCLINE; NALOXONE; PHENIDONE; PIOGLITAZONE; SIMVASTATIN; UROCORTIN;

DOPAMINERGIC SYSTEM; HUMAN; IMMUNE SYSTEM; INFLAMMATION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW;

EID: 79952157789     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.4061/2011/487450     Document Type: Review

References (241)

1. Warner T. T., Schapira A. H. V., Tatton., Rascol., Kordower., Olanow., Beal., Marek., Stocchi., Isacson., Genetic and environmental factors in the cause of Parkinson's disease Annals of Neurology 2003 53 3 S16 S25
2. Yacoubian T. A., Howard G., Kissela B., Sands C. D., Standaert D. G., Racial differences in parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: a cross-sectional study Neuroepidemiology 2009 33 4 329 334
3. Dahodwala N., Siderowf A., Xie M., Noll E., Stern M., Mandell D. S., Racial differences in the diagnosis of Parkinson's disease Movement Disorders 2009 24 8 1200 1205
4. Lai B. C. L., Marion S. A., Teschke K., Tsui J. K. C., Occupational and environmental risk factors for Parki (Pubitemid 34520454)
5. Lees A. J., Hardy J., Revesz T., Parkinson's disease The Lancet 2009 373 9680 2055 2066
6. Priyadarshi A., Khuder S. A., Schaub E. A., Priyadarshi S. S., Environmental risk factors and parkinson's disease: a metaanalysis Environmental Research 2001 86 2 122 127 (Pubitemid 32656305)
7. Bonifati V., Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics European Journal of Human Genetics 2006 14 10 1061 1062 (Pubitemid 44463961)
8. Westerlund M., Hoffer B., Olson L., Parkinson's disease: exit toxins, enter genetics Progress in Neurobiology 2010 90 2 146 156
9. Yao Z., Wood N. W., Cell death pathways in Parkinson's disease: role of mitochondria Antioxidants and Redox Signaling 2009 11 9 2135 2149
10. Chu C. T., Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism Biochimica et Biophysica Acta 2010 1802 1 20 28
11. Deas E., Wood N. W., Plun-Favreau H., Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochimica et Biophysica Acta. In press
12. Arduno D. M., Esteves A. R., Oliveira C. R., Cardoso S. M., Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease CNS and Neurological Disorders Drug Targets 2010 9 1 105 119
13. Witte M. E., Geurts J. J.G., de Vries H. E., van der Valk P., van Horssen J., Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 2010 10 5 411 418
14. Di Filippo M., Chiasserini D., Tozzi A., Picconi B., Calabresi P., Mitochondria and the link between neuroinflammation and neurodegeneration Journal of Alzheimer's Disease 2010 20 supplement 2 S369 S379
15. Beler H., Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease Experimental Neurology 2009 218 2 235 246
16. Lesage S., Brice A., Parkinson's disease: from monogenic forms to genetic susceptibility factors Human Molecular Genetics 2009 18 1 R48 R59
17. Jankovic J., Parkinson's disease: clinical features and diagnosis Journal of Neurology, Neurosurgery and Psychiatry 2008 79 4 368 376 (Pubitemid 351441488)
18. Branco D. M., Arduino D. M., Esteves A. R., Silva D. F., Cardoso S. M., Oliveira C. R., Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis Frontiers in Aging Neuroscience 2010 2 17
19. Schapira A. H. V., Emre M., Jenner P., Poewe W., Levodopa in the treatment of Parkinson's disease European Journal of Neurology 2009 16 9 982 989
20. Schober A., Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP Cell and Tissue Research 2004 318 1 215 224 (Pubitemid 39366054)
21. Ekstrand M. I., Galter D., The MitoPark Mousean animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons Parkinsonism and Related Disorders 2009 15 3 S185 S188
22. Goldberg M. S., Fleming S. M., Palacino J. J., Cepeda C., Lam H. A., Bhatnagar A., Meloni E. G., Wu N., Ackerson L. C., Klapstein G. J., Gajendiran M., Roth B. L., Chesselet M. F., Maidment N. T., Levine M. S., Shen J., Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons Journal of Biological Chemistry 2003 278 44 43628 43635 (Pubitemid 37345989)
23. Goldberg M. S., Pisani A., Haburcak M., Vortherms T. A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B. L., Pothos E. N., Calabresi P., Shen J., Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1 Neuron 2005 45 4 489 496 (Pubitemid 40249861)
24. Kitada T., Pisani A., Porter D. R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E. N., Shen J., Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice Proceedings of the National Academy of Sciences of the United States of America 2007 104 27 11441 11446 (Pubitemid 47175159)
25. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L., Dopaminergic loss and inclusion body formation in -synuclein mice: implications for neurodegenerative disorders Science 2000 287 5456 1265 1269 (Pubitemid 30112148)
26. Kahle P. J., Neumann M., Ozmen L., Mller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., Van Der Putten H., Probst A., Kremmer E., Kretzschmar H. A., Haass C., Subcellular localization of wild-type and Parkinson's disease-associated mutant -synuclein in human and transgenic mouse brain Journal of Neuroscience 2000 20 17 6365 6373
27. Abeliovich A., Schmitz Y., Farias I., Choi-Lundberg D., Ho W. H., Castillo P. E., Shinsky N., Garcia Verdugo J. M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A., Mice lacking -synuclein display functional deficits in the nigrostriatal dopamine system Neuron 2000 25 1 239 252 (Pubitemid 30316525)
28. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 1988 38 8 1285 1291
29. Tansey M. G., McCoy M. K., Frank-Cannon T. C., Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention Experimental Neurology 2007 208 1 1 25 (Pubitemid 47603240)
30. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T., Tumor necrosis factor- (TNF- ) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neuroscience Letters 1994 165 1-2 208 210
31. Blum-Degena D., Mller T., Kuhn W., Gerlach M., Przuntek H., Riederer P., Interleukin-1 and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neuroscience Letters 1995 202 1-2 17 20
32. Ton T. G., Heckbert S. R., Longstreth W. T. Jr., Rossing M. A., Kukull W. A., Franklin G. M., Swanson P. D., Smith-Weller T., Checkoway H., Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease Movement Disorders 2006 21 7 964 969 (Pubitemid 44184597)
33. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397
34. Lee J. K., Tran T., Tansey M. G., Neuroinflammation in Parkinson's disease Journal of Neuroimmune Pharmacology 2009 4 4 419 429
35. McMillian M., Kong L. Y., Sawin S. M., Wilson B., Das K., Hudson P., Hong J. S., Bing G., Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures Biochemical and Biophysical Research Communications 1995 215 2 572 577
36. Castao A., Herrera A. J., Cano J., Machado A., Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system Journal of Neurochemistry 1998 70 4 1584 1592 (Pubitemid 28136972)
37. Banati R. B., Daniel S. E., Blunt S. B., Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Movement Disorders 1998 13 2 221 227 (Pubitemid 28127795)
38. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y., Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathologica 2003 106 6 518 526 (Pubitemid 37441607)
39. Mogi M., Harada M., Kondob T., Riederer P., Inagaki H., Minami M., Nagatsu T., Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor- are elevated in the brain from parkinsonian patients Neuroscience Letters 1994 180 2 147 150
40. Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T., Transforming growth factor- 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease Neuroscience Letters 1995 193 2 129 132
41. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T., Brain -microglobulin levels are elevated in the striatum in Parkinson's disease Journal of Neural TransmissionParkinson's Disease and Dementia Section 1995 9 1 87 92
42. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T., Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain Journal of Neural Transmission 1996 103 8-9 1077 1081 (Pubitemid 26383837)
43. Stypua G., Kunert-Radek J., Stepie H., Zyliska K., Pawlikowski M., Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease NeuroImmunoModulation 1996 3 2-3 131 134 (Pubitemid 26373868)
44. Dobbs R. J., Charlett A., Purkiss A. G., Dobbs S. M., Weller C., Peterson D. W., Association of circulating TNF- and IL-6 with ageing and parkinsonism Acta Neurologica Scandinavica 1999 100 1 34 41 (Pubitemid 29292549)
45. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G. P., Rombos A., Zoga M., Tsoutsou A., Boufidou F., Kapaki E., Vassilopoulos D., Circulating interleukin-15 and RANTES chemokine in Parkinson's disease Acta Neurologica Scandinavica 2007 116 6 374 379 (Pubitemid 350045501)
46. Fiszer U., Mix E., Fredrikson S., Kostulas V., Olsson T., Link H., T cells are increased in patients with Parkinson's disease Journal of the Neurological Sciences 1994 121 1 39 45
47. Bas J., Calopa M., Mestre M., Mollev D. G., Cutillas B., Ambrosio S., Buendia E., Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism Journal of Neuroimmunology 2001 113 1 146 152 (Pubitemid 32008680)
48. Banati R. B., Visualising microglial activation in vivo GLIA 2002 40 2 206 217 (Pubitemid 35337378)
49. Ouchi Y., Kanno T., Okada H., Yoshikawa E., Futatsubashi M., Nobezawa S., Torizuka T., Sakamoto M., Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study Annals of Neurology 1999 46 5 723 731 (Pubitemid 29518133)
50. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T., Microglial activation and dopamine terminal loss in early Parkinson's disease Annals of Neurology 2005 57 2 168 175 (Pubitemid 40179853)
51. Liu B., Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease AAPS Journal 2006 8 3 E606 E621
52. Krger R., Hardt C., Tschentscher F., Jckel S., Kuhn W., Mller T., Werner J., Woitalla D., Berg D., Khnl N., Fuchs G. A., Santos E. J. M., Przuntek H., Epplen J. T., Schls L., Riess O., Genetic analysis of immunomodulating factors in sporadic Parkinson's disease Journal of Neural Transmission 2000 107 5 553 562 (Pubitemid 30251739)
53. McGeer P. L., Yasojima K., McGeer E. G., Association of interleukin-1 polymorphisms with idiopathic Parkinson's disease Neuroscience Letters 2002 326 1 67 69 (Pubitemid 34607596)
54. Mattila K. M., Rinne J. O., Lehtimki T., Rytt M., Ahonen J. P., Hurme M., Association of an interleukin 1b gene polymorphism (-511) with Parkinson's disease in Finnish patients Journal of Medical Genetics 2002 39 6 400 402 (Pubitemid 34664972)
55. Schulte T., Schls L., Mller T., Woitalla D., Berger K., Krger R., Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease Neuroscience Letters 2002 326 1 70 72 (Pubitemid 34607597)
56. Mller J. C., Depboylu C., Klsch H., Lohmller F., Bandmann O., Gocke P., Du Y., Paus S., Wllner U., Gasser T., Oertel W. H., Klockgether T., Dodel R. C., Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease Neuroscience Letters 2004 359 3 195 197 (Pubitemid 38446670)
57. Lin J. J., Chen C. H., Yueh K. C., Chang C. Y., Lin S. Z., A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females Parkinsonism and Related Disorders 2006 12 1 9 13 (Pubitemid 43037147)
58. McGeer P. L., Schwab C., Parent A., Doudet D., Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration Annals of Neurology 2003 54 5 599 604 (Pubitemid 37346066)
59. Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., Mcauliffe W. G., Dawson V. L., Dawson T. M., Przedborski S., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nature Medicine 1999 5 12 1403 1409
60. Brochard V., Combadire B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J. M., Duyckaerts C., Flavell R. A., Hirsch E. C., Hunot S., Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease Journal of Clinical Investigation 2009 119 1 182 192
61. Kurkowska-Jastrzebska I., Wroska A., Kohutnicka M. S., Czlonkowski A., Czlonkowska A., The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine intoxication in mouse Experimental Neurology 1999 156 1 50 61 (Pubitemid 29152982)
62. Crotty S., Fitzgerald P., Tuohy E., Harris D. M., Fisher A., Mandel A., Bolton A. E., Sullivan A. M., Nolan Y., Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease European Journal of Neuroscience 2008 27 2 294 300
63. Depino A. M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., Del Rey A., Pitossi F. J., Oertel W. H., Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease European Journal of Neuroscience 2003 18 10 2731 2742 (Pubitemid 37542126)
64. Dutta G., Zhang P., Liu B., The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery Fundamental and Clinical Pharmacology 2008 22 5 453 464
65. Bronstein D. M., Perez-Otano I., Sun V., Mullis Sawin S. B., Chan J., Wu G. C., Hudson P. M., Kong L. Y., Hong J. S., McMillian M. K., Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures Brain Research 1995 704 1 112 116
66. Gayle D. A., Ling Z., Tong C., Landers T., Lipton J. W., Carvey P. M., Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-, interleukin-1, and nitric oxide Developmental Brain Research 2002 133 1 27 35 (Pubitemid 34146496)
67. Castao A., Herrera A. J., Cano J., Machado A., The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF- IL-1 IFN- Journal of Neurochemistry 2002 81 1 150 157 (Pubitemid 34808862)
68. Iravani M. M., Kashefi K., Mander P., Rose S., Jenner P., Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration Neuroscience 2002 110 1 49 58 (Pubitemid 34214759)
69. Herrera A. J., Castao A., Venero J. L., Cano J., Machado A., The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system Neurobiology of Disease 2000 7 4 429 447
70. Iravani M. M., Leung C. C. M., Sadeghian M., Haddon C. O., Rose S., Jenner P., The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation European Journal of Neuroscience 2005 22 2 317 330 (Pubitemid 41097605)
71. Gao H. M., Jiang J., Wilson B., Zhang W., Hong J. S., Liu B., Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease Journal of Neurochemistry 2002 81 6 1285 1297 (Pubitemid 34809262)
72. Choi D. Y., Liu M., Hunter R. L., Cass W. A., Pandya J. D., Sullivan P. G., Shin E. J., Kim H. C., Gash D. M., Bing G., Striatal neuroinflammation promotes parkinsonism in rats PLoS ONE 2009 4 5
73. Choi D. Y., Zhang J., Bing G., Aging enhances the neuroinflammatory response and -synuclein nitration in rats Neurobiology of Aging 2010 31 9 1649 1653
74. Hunter R. L., Liu M., Choi D. Y., Cass W. A., Bing G., Inflammation and age-related iron accumulation in F344 rats Current aging science 2008 1 2 112 121
75. Hunter R. L., Cheng B., Choi D. Y., Liu M., Liu S., Cass W. A., Bing G., Intrastriatal lipopolysaccharide injection induces Parkinsonism in C57/B6 mice Journal of Neuroscience Research 2009 87 8 1913 1921
76. Zhang J., Stanton D. M., Nguyen X. V., Liu M., Zhang Z., Gash D., Bing G., Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits Neuroscience 2005 135 3 829 838 (Pubitemid 41407745)
77. Gao H. M., Kotzbauer P. T., Uryu K., Leight S., Trojanowski J. Q., Lee V. M. Y., Neuroinflammation and oxidation/nitration of -synuclein linked to dopaminergic neurodegeneration Journal of Neuroscience 2008 28 30 7687 7698
78. Hunter R. L., Choi D. Y., Ross S. A., Bing G., Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats Neuroscience Letters 2008 432 3 198 201
79. Perry V. H., Contribution of systemic inflammation to chronic neurodegeneration Acta Neuropathologica 2010 120 3 277 286
80. Qin L., Wu X., Block M. L., Liu Y., Breese G. R., Hong J. S., Knapp D. J., Crews F. T., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration GLIA 2007 55 5 453 462 (Pubitemid 46383175)
81. Czapski G. A., Cakala M., Chalimoniuk M., Gajkowska B., Strosznajder J. B., Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation Journal of Neuroscience Research 2007 85 8 1694 1703 (Pubitemid 46849617)
82. Li G., Sun S., Cao X., Zhong J., Tong E., LPS-induced degeneration of dopaminergic neurons of substantia nigra in rats Journal of Huazhong University of Science and Technology 2004 24 1 83 86 (Pubitemid 41559694)
83. Lu X., Bing G., Hagg T., Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats Neuroscience 2000 97 2 285 291 (Pubitemid 30224766)
84. Maurio R., Machado A., Santiago M., Effect of in vivo striatal perfusion of lipopolysaccharide on dopamine metabolites Neuroscience Letters 2010 475 3 121 123
85. Kim W. G., Mohney R. P., Wilson B., Jeohn G. H., Liu B., Hong J. S., Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia Journal of Neuroscience 2000 20 16 6309 6316 (Pubitemid 30658427)
86. Cicchetti F., Brownell A. L., Williams K., Chen Y. I., Livni E., Isacson O., Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging European Journal of Neuroscience 2002 15 6 991 998 (Pubitemid 35463634)
87. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R. B., Brooks D. J., In vivo imaging of microglial activation with [C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiology of Disease 2006 21 2 404 412 (Pubitemid 43099863)
88. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T., Microglial activation and dopamine terminal loss in early Parkinson's disease Annals of Neurology 2005 57 2 168 175 (Pubitemid 40179853)
89. Ouchi Y., Yagi S., Yokokura M., Sakamoto M., Neuroinflammation in the living brain of Parkinson's disease Parkinsonism and Related Disorders 2009 15 supplement 3 S200 S204
90. Ito F., Toyama H., Kudo G., Suzuki H., Hatano K., Ichise M., Katada K., Ito K., Sawada M., Two activated stages of microglia and PET imaging of peripheral benzodiazepine receptors with [C]PK11195 in rats Annals of Nuclear Medicine 2010 24 3 163 169
91. Ariza D., Lima M. M. S., Moreira C. G., Dombrowski P. A., Avila T. V., Allemand A., B Mendes D. A. G., Cunha C. D., Vital M. A. B. F., Intranigral LPS Administration Produces Dopamine, Glutathione but not Behavioral Impairment in Comparison to MPTP and 6-OHDA Neurotoxin Models of Parkinson's Disease Neurochemical Research 2010 35 10 1620 1627
92. Byler S. L., Boehm G. W., Karp J. D., Kohman R. A., Tarr A. J., Schallert T., Barth T. M., Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice Behavioural Brain Research 2009 198 2 434 439
93. Panaro M. A., Lofrumento D. D., Saponaro C., De Nuccio F., Cianciulli A., Mitolo V., Nicolardi G., Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease Immunopharmacology and Immunotoxicology 2008 30 4 729 740
94. Koprich J. B., Reske-Nielsen C., Mithal P., Isacson O., Neuroinflammation mediated by IL-1 increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease Journal of Neuroinflammation 2008 5, article 8
95. Godoy M. C. P., Tarelli R., Ferrari C. C., Sarchi M. I., Pitossi F. J., Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease Brain 2008 131 7 1880 1894 (Pubitemid 351957456)
96. Jung B. D., Shin E. J., Nguyen X. K. T., Jin C. H., Bach J. H., Park S. J., Nah S. Y., Wie M. B., Bing G., Kim H. C., Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration Neurochemistry International 2010 56 2 229 244
97. Mangano E. N., Hayley S., Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: neuroimmune sensitization of neurodegeneration Neurobiology of Aging 2009 30 9 1361 1378
98. Purisai M. G., McCormack A. L., Cumine S., Li J., Isla M. Z., Di Monte D. A., Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration Neurobiology of Disease 2007 25 2 392 400 (Pubitemid 46124019)
99. Frank-Cannon T. C., Tran T., Ruhn K. A., Martinez T. N., Hong J., Marvin M., Hartley M., Trevio I., O'Brien D. E., Casey B., Goldberg M. S., Tansey M. G., Parkin deficiency increases vulnerability to inflammation-related nigral degeneration Journal of Neuroscience 2008 28 43 10825 10834
100. Barlow B. K., Cory-Slechta D. A., Richfield E. K., Thiruchelvam M., The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder Reproductive Toxicology 2007 23 3 457 470 (Pubitemid 46628874)
101. Ling Z. D., Gayle D. A., Ma S. Y., Lipton J. W., Tong C. W., Hong J. S., Carvey P. M., In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain Movement Disorders 2002 17 1 116 124 (Pubitemid 36041267)
102. Carvey P. M., Chang Q., Lipton J. W., Ling Z., Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease Frontiers in Bioscience 2003 8 s826 s837
103. Ling Z., Chang Q. A., Tong C. W., Leurgans S. E., Lipton J. W., Carvey P. M., Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally Experimental Neurology 2004 190 2 373 383 (Pubitemid 39504993)
104. Ling Z. D., Chang Q., Lipton J. W., Tong C. W., Landers T. M., Carvey P. M., Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain Neuroscience 2004 124 3 619 628 (Pubitemid 38258285)
105. Ling Z., Zhu Y., Tong C. w., Snyder J. A., Lipton J. W., Carvey P. M., Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally Experimental Neurology 2006 199 2 499 512 (Pubitemid 43928976)
106. Zhu Y., Carvey P. M., Ling Z., Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide Neurochemistry International 2007 50 4 671 680 (Pubitemid 46329837)
107. Ling Z., Zhu Y., Tong C. W., Snyder J. A., Lipton J. W., Carvey P. M., Prenatal lipopolysaccharide does not accelerate progressive dopamine neuron loss in the rat as a result of normal aging Experimental Neurology 2009 216 2 312 320
108. Kirsten T. B., Taricano M., Flrio J. C., Palermo-Neto J., Bernardi M. M., Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring Behavioural Brain Research 2010 211 1 77 82
109. Wang S., Yan J. Y., Lo YU. K., Carvey P. M., Ling Z., Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide Brain Research 2009 1265 196 204
110. Sawada H., Suzuki H., Nagatsu T., Sawada M., Neuroprotective and neurotoxic phenotypes of activated microglia in neonatal mice with respective MPTP-and ethanol-induced brain injury Neurodegenerative Diseases 2010 7 13 64 67
111. Sawada M., Sawada H., Nagatsu T., Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases Neurodegenerative Diseases 2008 5 3-4 254 256 (Pubitemid 351347865)
112. Sawada H., Hishida R., Hirata Y., Ono K., Suzuki H., Muramatsu S. I., Nakano I., Nagatsu T., Sawada M., Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Journal of Neuroscience Research 2007 85 8 1752 1761 (Pubitemid 46849623)
113. Long-Smith C. M., Sullivan A. M., Nolan Y. M., The influence of microglia on the pathogenesis of Parkinson's disease Progress in Neurobiology 2009 89 3 277 287
114. Brown G. C., Neher J. J., Inflammatory neurodegeneration and mechanisms of microglial killing of neurons Molecular Neurobiology 2010 1 6
115. Anderson K. V., Bokla L., Nusslein-Volhard C., Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product Cell 1985 42 3 791 798 (Pubitemid 16083720)
116. Hashimoto C., Hudson K. L., Anderson K. V., The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein Cell 1988 52 2 269 279
117. Medzhitov R., Preston-Hurlburt P., Janeway C. A. Jr., A human homologue of the Drosophila toll protein signals activation of adaptive immunity Nature 1997 388 6640 394 397 (Pubitemid 27334820)
118. Gangloff M., Weber A. N.R., Gibbard R. J., Gay N. J., Evolutionary relationships, but functional differences, between the Drosophila and human Toll-like receptor families Biochemical Society Transactions 2003 31 3 659 663 (Pubitemid 36750751)
119. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M., MD-2, a molecule that confers lipopolysaccharide responsiveness on toll- like receptor 4 Journal of Experimental Medicine 1999 189 11 1777 1782 (Pubitemid 29272694)
120. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., Kitamura T., Kosugi A., Kimoto M., Miyake K., Essential role of MD-2 in LPS responsiveness and TLR4 distribution Nature Immunology 2002 3 7 667 672 (Pubitemid 34752476)
121. Kobayashi M., Saitoh S. I., Tanimura N., Takahashi K., Kawasaki K., Nishijima M., Fujimoto Y., Fukase K., Akashi-Takamura S., Miyake K., Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering Journal of Immunology 2006 176 10 6211 6218
122. Horng T., Barton G. M., Flavell R. A., Medzhitov R., The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors Nature 2002 420 6913 329 333 (Pubitemid 35398189)
123. Kawai T., Akira S., Signaling to NF- B by Toll-like receptors Trends in Molecular Medicine 2007 13 11 460 469
124. Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity Cell 2006 124 4 783 801 (Pubitemid 43261452)
125. Rowe D. C., McGettrick A. F., Latz E., Monks B. G., Gay N. J., Yamamoto M., Akira S., O'Neill L. A., Fitzgerald K. A., Golenbock D. T., The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction Proceedings of the National Academy of Sciences of the United States of America 2006 103 16 6299 6304
126. Tanimura N., Saitoh S., Matsumoto F., Akashi-Takamura S., Miyake K., Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling Biochemical and Biophysical Research Communications 2008 368 1 94 99
127. Hcker H., Redecke V., Blagoev B., Kratchmarova I., Hsu LI. C., Wang G. G., Kamps M. P., Raz E., Wagner H., Hcker G., Mann M., Karin M., Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6 Nature 2006 439 7073 204 207 (Pubitemid 43083141)
128. Poikonen K., Lajunen T., Silvennoinen-Kassinen S., Leinonen M., Saikku P., Effects of CD14, TLR2, TLR4, LPB, and IL-6 gene polymorphisms on chlamydia pneumoniae growth in human macrophages in vitro Scandinavian Journal of Immunology 2009 70 1 34 39
129. Knott A. B., Bossy-Wetzel E., Nitric oxide in health and disease of the nervous system Antioxidants and Redox Signaling 2009 11 3 541 553
130. Singh S., Das T., Ravindran A., Chaturvedi R. K., Shukla Y., Agarwal A. K., Dikshit M., Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease Redox Report 2005 10 2 103 109 (Pubitemid 44110218)
131. Singh S., Kumar S., Dikshit M., Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide Redox Report 2010 15 3 115 122
132. Ruano D., Revilla E., Paz Gaviln M., Vizuete M. L., Pintado C., Vitorica J., Castao A., Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection Neuroscience 2006 140 4 1157 1168 (Pubitemid 43928265)
133. Arimoto T., Bing G., Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration Neurobiology of Disease 2003 12 1 35 45 (Pubitemid 36259966)
134. Tsang A. H. K., Chung K. K. K., Oxidative and nitrosative stress in Parkinson's disease Biochimica et Biophysica Acta 2009 1792 7 643 650
135. Szab C., Ischiropoulos H., Radi R., Peroxynitrite: biochemistry, pathophysiology and development of therapeutics Nature Reviews Drug Discovery 2007 6 8 662 680 (Pubitemid 47207751)
136. Kahle P. J., Waak J., Gasser T., DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders Free Radical Biology and Medicine 2009 47 10 1354 1361
137. Waak J., Weber S. S., Waldenmaier A., Grner K., Alunni-Fabbroni M., Schell H., Vogt-Weisenhorn D., Pham T. T., Reumers V., Baekelandt V., Wurst W., Kahle P. J., Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1 FASEB Journal 2009 23 8 2478 2489
138. Wang T., Qin L., Liu B., Liu Y., Wilson B., Eling T. E., Langenbach R., Taniura S., Hong J. S., Role of reactive oxygen species in LPS-induced production of prostaglandin E in microglia Journal of Neurochemistry 2004 88 4 939 947 (Pubitemid 38199315)
139. Qin L., Block M. L., Liu Y., Bienstock R. J., Pei Z., Zhang W., Wu X., Wilson B., Burka T., Hong J. S., Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress FASEB Journal 2005 19 6 550 557 (Pubitemid 40471246)
140. Qin L., Liu Y., Wang T., Wei S. J., Block M. L., Wilson B., Liu B., Hong J. S., NADPH Oxidase Mediates Lipopolysaccharide-induced Neurotoxicity and
141. Chret C., Gervais A., Lelli A., Colin C., Amar L., Ravassard P., Mallet J., Cumano A., Krause K. H., Mallat M., Neurotoxic activation of microglia is promoted by a Nox1-dependent NADPH oxidase Journal of Neuroscience 2008 28 46 12039 12051
142. Qin L., Li G., Qian X., Liu Y., Wu X., Liu B., Hong J. S., Block M. L., Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation GLIA 2005 52 1 78 84 (Pubitemid 41532140)
143. Pei Z., Pang H., Qian LI., Yang S., Wang T., Zhang W., Wu X., Dallas S., Wilson B., Reece J. M., Miller D. S., Hong J. S., Block M. L., MAC1 mediates LPS-induced production of superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity GLIA 2007 55 13 1362 1373 (Pubitemid 47328939)
144. Hu X., Zhang D., Pang H., Caudle W. M., Li Y., Gao H., Liu Y., Qian LI., Wilson B., Di Monte D. A., Ali S. F., Zhang J., Block M. L., Hong J. S., Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Journal of Immunology 2008 181 10 7194 7204
145. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F., Joh T. H., Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia Journal of Neuroscience 2005 25 14 3701 3711
146. McCoy M. K., Tansey M. G., TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease Journal of Neuroinflammation 2008 5, article 45
147. Qian L., Wei S.-J., Zhang D., Hu X., Xu Z., Wilson B., El-Benna J., Hong J.-S., Flood P. M., Potent anti-inflammatory and neuroprotective effects of tgf- 1 are mediated through the inhibition of erk and p47phox-Ser345 phosphorylation and translocation in microglia Journal of Immunology 2008 181 1 660 668
148. Arimoto T., Choi D. Y., Lu X., Liu M., Nguyen X. V., Zheng N., Stewart C. A., Kim H. C., Bing G., Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra Neurobiology of Aging 2007 28 6 894 906 (Pubitemid 46589742)
149. Zhang F., Qian LI., Flood P. M., Shi J. S., Hong J. S., Gao H. M., Inhibition of I B kinase- protects dopamine neurons against lipopolysaccharide- induced neurotoxicity Journal of Pharmacology and Experimental Therapeutics 2010 333 3 822 833
150. Lund S., Porzgen P., Mortensen A. L., Hasseldam H., Bozyczko-Coyne D., Morath S., Hartung T., Bianchi M., Ghezzi P., Bsibsi M., Dijkstra S., Leist M., Inhibition of microglial inflammation by the MLK inhibitor CEP-1347 Journal of Neurochemistry 2005 92 6 1439 1451 (Pubitemid 40389213)
151. Cimino P. J., Keene C. D., Breyer R. M., Montine K. S., Montine T. J., Therapeutic targets in prostaglandin E signaling for neurologic disease Current Medicinal Chemistry 2008 15 19 1863 1869
152. Jin J., Shie F.-S., Liu J., Wang Y., Davis J., Schantz A. M., Montine K. S., Montine T. J., Zhang J., Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated -synuclein Journal of Neuroinflammation 2007 4, article 2
153. Hunter R. L., Dragicevic N., Seifert K., Choi D. Y., Liu M., Kim H. C., Cass W. A., Sullivan P. G., Bing G., Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system Journal of Neurochemistry 2007 100 5 1375 1386
154. de Meira Santos Lima M., Braga Reksidler A., Marques Zanata S., Bueno Machado H., Tufik S., Vital M. A. B. F., Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats Brain Research 2006 1101 1 117 125 (Pubitemid 44036768)
155. Sui YI., Stani D., Tomas D., Jarrott B., Horne M. K., Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta Neuroscience Letters 2009 460 2 121 125
156. Li Z., Choi D. Y., Shin E. J., Hunter R. L., Jin C. H., Wie M. B., Kim M. S., Park S. J., Bing G., Kim H. C., Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity Neuroscience Letters 2008 445 1 1 6
157. Ikeda-Matsuo Y., Ikegaya Y., Matsuki N., Uematsu S., Akira S., Sasaki Y., Microglia-specific expression of microsomal prostaglandin E synthase-1 contributes to lipopolysaccharide-induced prostaglandin E production Journal of Neurochemistry 2005 94 6 1546 1558 (Pubitemid 41324637)
158. de Oliveira A. C. P., Cadelario-Jalil E., Bhatia H. S., Lieb K., Hll M., Fiebich B. L., Regulation of prostaglandin E synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2 GLIA 2008 56 8 844 855
159. Matsui T., Svensson C. I., Hirata Y., Mizobata K., Hua X. Y., Yaksh T. L., Release of prostaglandin E2 and nitric oxide from spinal microglia is dependent on activation of p38 mitogen-activated protein kinase Anesthesia amp; Analgesia 2010 111 2 554 560
160. Zhang D., Hu X., Qian LI., Wilson B., Lee C., Flood P., Langenbach R., Hong J. S., Prostaglandin E2 released from activated microglia enhances astrocyte proliferation in vitro Toxicology and Applied Pharmacology 2009 238 1 64 70
161. Yoon S. K., Dong H. C., Block M. L., Lorenzl S., Yang L., Youn J. K., Sugama S., Byung P. C., Hwang O., Browne S. E., Soo Y. K., Hong J. S., Beal M. F., Joh T. H., A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation FASEB Journal 2007 21 1 179 187 (Pubitemid 46052555)
162. Lee E.-J., Woo M.-S., Moon P.-G., Baek M.-C., Choi I.-Y., Kim W.-K., Junn E., Kim H.-S., -synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1 Journal of Immunology 2010 185 1 615 623
163. McClain J. A., Phillips L. L., Fillmore H. L., Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration Neuroscience Letters 2009 460 1 27 31
164. Cho Y., Son H. J., Kim E. M., Choi JI. H., Kim S. T., Ji IN. J., Choi D. H., Joh T. H., Kim Y. S., Hwang O., Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3 Neurotoxicity Research 2009 16 4 361 371
165. McGeer P. L., McGeer E. G., Glial reactions in Parkinson's disease Movement Disorders 2008 23 4 474 483
166. Sofroniew M. V., Vinters H. V., Astrocytes: biology and pathology Acta Neuropathologica 2010 119 1 7 35
167. Chung Y. C., Ko H. W., Bok E., Park E. S., Huh S. H., Nam J. H., Jin B. K., The role of neuroinflammation on the pathogenesis of Parkinson's disease BMB Reports 2010 43 4 225 232
168. Song Y. J. C., Halliday G. M., Holton J. L., Lashley T., Osullivan S. S., McCann H., Lees A. J., Ozawa T., Williams D. R., Lockhart P. J., Revesz T. R., Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression Journal of Neuropathology and Experimental Neurology 2009 68 10 1073 1083
169. Choi D. K., Pennathur S., Perier C., Tieu K., Teismann P., Wu DU. C., Jackson-Lewis V., Vila M., Vonsattel J. P., Heinecke J. W., Przedborski S., Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice Journal of Neuroscience 2005 25 28 6594 6600 (Pubitemid 40995291)
170. Kipp M., Norkute A., Johann S., Lorenz L., Braun A., Hieble A., Gingele S., Pott F., Richter J., Beyer C., Brain-region-specific astroglial responses in vitro after LPS exposure Journal of Molecular Neuroscience 2008 35 2 235 243
171. Ji K. A., Eu MI. Y., Kang S. H., Gwag B. J., Jou I., Joe E. H., Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex GLIA 2008 56 10 1039 1047
172. Zhang P., Lokuta K. M., Turner D. E., Liu B., Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia Journal of Neurochemistry 2010 112 2 434 443
173. Liddell J. R., Robinson S. R., Dringen R., Bishop G. M., Astrocytes retain their antioxidant capacity into advanced old age GLIA 2010 58 12 1500 1509
174. Mullett S. J., Hinkle D. A., DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone Neurobiology of Disease 2009 33 1 28 36
175. Clements C. M., McNally R. S., Conti B. J., Mak T. W., Ting J. P. Y., DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 Proceedings of the National Academy of Sciences of the United States of America 2006 103 41 15091 15096 (Pubitemid 44583169)
176. Gan LI., Johnson D. A., Johnson J. A., Keap1-Nrf2 activation in the presence and absence of DJ-1 European Journal of Neuroscience 2010 31 6 967 977
177. Vargas M. R., Johnson J. A., The Nrf2-ARE cytoprotective pathway in astrocytes Expert Reviews in Molecular Medicine 2009 11, article e17
178. Burton N. C., Kensler T. W., Guilarte T. R., In vivo modulation of the Parkinsonian phenotype by Nrf2 NeuroToxicology 2006 27 6 1094 1100 (Pubitemid 44838961)
179. Jakel R. J., Townsend J. A., Kraft A. D., Johnson J. A., Nrf2-mediated protection against 6-hydroxydopamine Brain Research 2007 1144 1 192 201 (Pubitemid 46440842)
180. Chen P. C., Vargas M. R., Pani A. K., Smeyne R. J., Johnson D. A., Kan Y. W., Johnson J. A., Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2933 2938
181. Rojo A. I., Innamorato N. G., Martn-Moreno A. M., De Ceballos M. L., Yamamoto M., Cuadrado A., Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease GLIA 2010 58 5 588 598
182. von Otter M., Landgren S., Nilsson S., Celojevic D., Bergstrm P., Hkansson A., Nissbrandt H., Drozdzik M., Bialecka M., Kurzawski M., Blennow K., Nilsson M., Hammarsten O., Zetterberg H., Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease BMC Medical Genetics 2010 11 1, article 36
183. Beal M. F., Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease Parkinsonism and Related Disorders 2009 15 3 S189 S194
184. Yang L., Calingasan N. Y., Thomas B., Charturvedi R. K., Kiaei M., Wille E. J., Liby K. T., Williams C., Royce D., Risingson R., Musiek E. S., Morrow J. D., Sporn M., Beal M. F., Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription PLoS ONE 2009 4 6
185. Brandenburg L. O., Kipp M., Lucius R., Pufe T., Wruck C. J., Sulforaphane suppresses LPS-induced inflammation in primary rat microglia Inflammation Research 2010 59 6 443 450
186. Innamorato N. G., Lastres-Becker I., Cuadrado A., Role of microglial redox balance in modulation of neuroinflammation Current Opinion in Neurology 2009 22 3 308 314
187. Kong X., Thimmulappa R., Kombairaju P., Biswal S., NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice Journal of Immunology 2010 185 1 569 577
188. Biswas S. K., Lopez-Collazo E., Endotoxin tolerance: new mechanisms, molecules and clinical significance Trends in Immunology 2009 30 10 475 487
189. Ding Y. E., Li L., Lipopolysaccharide preconditioning induces protection against lipopolysaccharide-induced neurotoxicity in organotypic midbrain slice culture Neuroscience Bulletin 2008 24 4 209 218
190. Min K. J., Yang M. S., Kim S. U., Jou I., Joe E. H., Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation Journal of Neuroscience 2006 26 6 1880 1887 (Pubitemid 43237001)
191. Innamorato N. G., Jazwa A., Rojo A. I., Garca C., Ferna ndez-Ruiz J., Grochot-Przeczek A., Stachurska A., Jozkowicz A., Dulak J., Cuadrado A., Different susceptibility to the parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1 PLoS ONE 2010 5 7
192. Zlokovic B. V., The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders Neuron 2008 57 2 178 201
193. Kortekaas R., Leenders K. L., Van Oostrom J. C. H., Vaalburg W., Bart J., Willemsen A. T. M., Hendrikse N. H., Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo Annals of Neurology 2005 57 2 176 179 (Pubitemid 40179854)
194. Toms-Camardiel M., Rite I., Herrera A. J., De Pablos R. M., Cano J., Machado A., Venero J. L., Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system Neurobiology of Disease 2004 16 1 190 201 (Pubitemid 38569810)
195. Sumi N., Nishioku T., Takata F., Matsumoto J., Watanabe T., Shuto H., Yamauchi A., Dohgu S., Kataoka Y., Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia Cellular and Molecular Neurobiology 2010 30 2 247 253
196. Rezai-Zadeh K., Gate D., Town T., CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? Journal of Neuroimmune Pharmacology 2009 4 4 462 475
197. Ji K. A., Yang M. S., Jeong H. K., Min K. J., Kang S. H., Jou I., Joe E. H., Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain GLIA 2007 55 15 1577 1588 (Pubitemid 47556261)
198. Stone D. K., Reynolds A. D., Mosley R. L., Gendelman H. E., Innate and adaptive immunity for the pathobiology of Parkinson's disease Antioxidants and Redox Signaling 2009 11 9 2151 2166
199. McGeer P. L., McGeer E. G., Inflammation and neurodegeneration in Parkinson's disease Parkinsonism and Related Disorders 2004 10 1 S3 S7
200. Brochard V., Combadire B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J. M., Duyckaerts C., Flavell R. A., Hirsch E. C., Hunot S., Infiltration of CD4 lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease Journal of Clinical Investigation 2009 119 1 182 192
201. Appel S. H., CD4+ T cells mediate cytotoxicity in neurodegenerative diseases Journal of Clinical Investigation 2009 119 1 13 15
202. Reynolds A. D., Banerjee R., Liu J., Gendelman H. E., Mosley R. L., Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease Journal of Leukocyte Biology 2007 82 5 1083 1094 (Pubitemid 350133504)
203. Reynolds A. D., Stone D. K., Hutter J. A. L., Benner E. J., Mosley R. L., Gendelman H. E., Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease Journal of Immunology 2010 184 5 2261 2271
204. Reynolds A. D., Stone D. K., Mosley R. L., Gendelman H. E., Nitrated -synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets Journal of Immunology 2009 182 7 4137 4149
205. Appel S. H., Beers D. R., Henkel J. S., T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends in Immunology 2010 31 1 7 17
206. Griffiths M., Neal J. W., Gasque P., Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins International Review of Neurobiology 2007 82 29 55
207. Lee HE. J., Suk JI. E., Patrick C., Bae E. J., Cho JI. H., Rho S., Hwang D., Masliah E., Lee S. J., Direct transfer of -synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies Journal of Biological Chemistry 2010 285 12 9262 9272
208. Xie L., Poteet E. C., Li W., Scott A. E., Liu R., Wen Y., Ghorpade A., Simpkins J. W., Yang S., Modulation of polymorphonuclear neutrophil functions by astrocytes Journal of Neuroinflammation 2010 7 1, article 53
209. Teismann P., Tieu K., Choi D. K., Wu DU. C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S., Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proceedings of the National Academy of Sciences of the United States of America 2003 100 9 5473 5478 (Pubitemid 36542729)
210. Vijitruth R., Liu M., Choi D.-Y., Nguyen X. V., Hunter R. L., Bing G., Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease Journal of Neuroinflammation 2006 3, article 6
211. Carrasco E., Casper D., Werner P., Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity Journal of Neuroscience Research 2005 81 1 121 131 (Pubitemid 41139117)
212. Chen H., Jacobs E., Schwarzschild M. A., McCullough M. L., Calle E. E., Thun M. J., Ascherio A., Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Annals of Neurology 2005 58 6 963 967 (Pubitemid 41746889)
213. Gagne J. J., Power M. C., Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis Neurology 2010 74 12 995 1002
214. Samii A., Etminan M., Wiens M. O., Jafari S., NSAID use and the risk of parkinsons disease: systematic review and meta-analysis of observational studies Drugs and Aging 2009 26 9 769 779
215. De Gaetano G., Donati M. B., Cerletti C., Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors Trends in Pharmacological Sciences 2003 24 5 245 252 (Pubitemid 36588873)
216. Klegeris A., McGeer P. L., Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity Neurobiology of Aging 2002 23 5 787 794 (Pubitemid 35217703)
217. Hernn M. A., Takkouche B., Caamao-Isorna F., Gestal-Otero J. J., A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease Annals of Neurology 2002 52 3 276 284 (Pubitemid 35001493)
218. Shytle R. D., Mori T., Townsend K., Vendrame M., Sun N., Zeng J., Ehrhart J., Silver A. A., Sanberg P. R., Tan J., Cholinergic modulation of microglial activation by 7 nicotinic receptors Journal of Neurochemistry 2004 89 2 337 343 (Pubitemid 38495982)
219. Park H. J., Lee P. H., Ahn Y. W., Choi Y. J., Lee G., Lee DA. Y., Chung E. S., Jin B. K., Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action European Journal of Neuroscience 2007 26 1 79 89 (Pubitemid 47035441)
220. Woster A. P., Combs C. K., Differential ability of a thiazolidinedione PPAR agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells Journal of Neurochemistry 2007 103 1 67 76 (Pubitemid 47404200)
221. Patel R. N., Attur M. G., Dave M. N., Patel I. V., Stuchin S. A., Abramson S. B., Amin A. R., A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E production Journal of Immunology 1999 163 6 3459 3467 (Pubitemid 29431850)
222. Liu B., Jiang J. W., Wilson B. C., Du L., Yang S. N., Wang J. Y., Wu G. C., Cao X. D., Hong J. S., Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide Journal of Pharmacology and Experimental Therapeutics 2000 295 1 125 132
223. Crisby M., Carlson L. A., Winblad B., Statins in the prevention and treatment of Alzheimer disease Alzheimer Disease and Associated Disorders 2002 16 3 131 136 (Pubitemid 35001087)
224. Stanislaus R., Gilg A. G., Singh A. K., Singh I., Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin Neuroscience Letters 2002 333 3 167 170 (Pubitemid 35335769)
225. Vaughan C. J., Delanty N., Neuroprotective properties of statins in cerebral ischemia and stroke Stroke 1999 30 9 1969 1973 (Pubitemid 29411843)
226. Selley M. L., Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice Brain Research 2005 1037 1-2 1 6 (Pubitemid 40362375)
227. Hernndez-Romero M. D. C., Argelles S., Villarn R. F., De Pablos R. M., Delgado-Corts M. J., Santiago M., Herrera A. J., Cano J., Machado A., Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide Journal of Neurochemistry 2008 105 2 445 459 (Pubitemid 351490015)
228. Santiago M., Hernndez-Romero M. C., Machado A., Cano J., Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not European Journal of Pharmacology 2009 609 1-3 58 64
229. Oldberg A., Franzen A., Heinegard D., Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence Proceedings of the National Academy of Sciences of the United States of America 1986 83 23 8819 8823 (Pubitemid 17223492)
230. Iczkiewicz J., Jackson M. J., Smith L. A., Rose S., Jenner P., Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease Brain Research 2006 1118 1 239 250 (Pubitemid 44740248)
231. Iczkiewicz J., Rose S., Jenner P., Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat European Journal of Neuroscience 2005 21 7 1911 1920 (Pubitemid 40685869)
232. Meller R., Stevens S. L., Minami M., Cameron J. A., King S., Rosenzweig H., Doyle K., Lessov N. S., Simon R. P., Stenzel-Poore M. P., Neuroprotection by osteopontin in stroke Journal of Cerebral Blood Flow and Metabolism 2005 25 2 217 225 (Pubitemid 40171203)
233. Iczkiewicz J., Broom L., Cooper J. D., Wong A. M.S., Rose S., Jenner P., The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra Journal of Neurochemistry 2010 114 6 1792 1804
234. Choi J.-S., Pham T. T.H., Jang Y.-J., Bao C. B., Lee B.-H., Joo K.-M., Cha C.-I., Lee K.-H., Corticotropin-releasing factor (CRF) and urocortin promote the survival of cultured cerebellar GABAergic neurons through the Type 1 CRF receptor Journal of Korean Medical Science 2006 21 3 518 526 (Pubitemid 43926000)
235. Facci L., Stevens D. A., Pangallo M., Franceschini D., Skaper S. D., Strijbos P. J. L. M., Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors Neuropharmacology 2003 45 5 623 636 (Pubitemid 36980819)
236. Pedersen W. A., Wan R., Zhang P., Mattson M. P., Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I Journal of Neuroscience 2002 22 2 404 412 (Pubitemid 34049078)
237. Abuirmeileh A., Lever R., Kingsbury A. E., Lees A. J., Locke I. C., Knight R. A., Chowdrey H. S., Biggs C. S., Whitton P. S., The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease European Journal of Neuroscience 2007 26 2 417 423 (Pubitemid 47087603)
238. Abuirmeileh A., Harkavyi A., Kingsbury A., Lever R., Whitton P. S., The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide Journal of the Neurological Sciences 2008 271 1-2 131 136
239. Abuirmeileh A., Harkavyi A., Kingsbury A., Lever R., Whitton P. S., The CRF-like peptide urocortin greatly attenuates loss of extracellular striatal dopamine in rat models of Parkinson's disease by activating CRF receptors European Journal of Pharmacology 2009 604 13 45 50
240. Argelles S., Venero J. L., Garca-Rodriguez S., Tomas-Camardiel M., Ayala A., Cano J., Machado A., Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson's disease Neurochemistry International 2010 57 3 227 234
241. Sloane J. A., Blitz D., Margolin Z., Vartanian T., A clear and present danger: endogenous ligands of Toll-like receptors NeuroMolecular Medicine 2009 12 2 149 163